17.33
+0.1(+0.58%)
Currency In USD
| Previous Close | 17.23 |
| Open | 17.31 |
| Day High | 17.6 |
| Day Low | 17.04 |
| 52-Week High | 18.41 |
| 52-Week Low | 3.18 |
| Volume | 174,925 |
| Average Volume | 245,998 |
| Market Cap | 464.75M |
| PE | -115.53 |
| EPS | -0.15 |
| Moving Average 50 Days | 14.53 |
| Moving Average 200 Days | 10.78 |
| Change | 0.1 |
If you invested $1000 in Eton Pharmaceuticals, Inc. (ETON) since IPO date, it would be worth $2,772.8 as of May 09, 2025 at a share price of $17.33. Whereas If you bought $1000 worth of Eton Pharmaceuticals, Inc. (ETON) shares 5 years ago, it would be worth $3,133.82 as of May 09, 2025 at a share price of $17.33.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
GlobeNewswire Inc.
May 01, 2025 8:30 PM GMT
DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
GlobeNewswire Inc.
Apr 28, 2025 10:50 AM GMT
- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
GlobeNewswire Inc.
Apr 01, 2025 11:00 AM GMT
Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S.DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company foc